Skip to main content
Research

Publications: Prof David Baker

Schmierer K, Sørensen PS, Baker D ( 2021 ) . Highly effective disease-modifying treatment as initial MS therapy . Curr Opin Neurol vol. 34 , ( 3 ) 286 - 294 .
Galvin SG, Larraufie P, Kay RG, Pitt H, Bernard E, McGavigan AK, Brant H, Hood J et al. ( 2021 ) . Peptidomics of enteroendocrine cells and characterisation of potential effects of a novel preprogastrin derived-peptide on glucose tolerance in lean mice . Peptides vol. 140 ,
Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, Gnanapavan S, Marta M et al. ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Mult Scler Relat Disord vol. 52 ,
Smets I, Reyes S, Baker D, Giovannoni G ( 2021 ) . Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment . Multiple Sclerosis and Related Disorders vol. 50 ,
Roth E, Benoit S, Quentin B, Lam B, Will S, Ma M, Heeley N, Darwish T et al. ( 2021 ) . Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy . Molecular Metabolism vol. 43 ,
Thomson A, Dobson R, Baker D, Giovannoni G ( 2021 ) . Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families . Multiple Sclerosis and Related Disorders vol. 47 ,
Munger K, Kang A, Baker D, Goodman A, Samkoff L ( 2020 ) . Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 258 - 258 .
Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .
Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J et al. ( 2020 ) . Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS) . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 212 - 213 .
Mateo-Casas M, Reyes S, De Trane S, Edwards F, Espasandin M, Anjorin G, Baker D, Schmierer K et al. ( 2020 ) . Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? . eNeurologicalSci vol. 21 ,
Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M et al. ( 2020 ) . Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis . Journal of Neurology, Neurosurgery and Psychiatry
Ford BE, Chachra SS, Alshawi A, Brennan A, Harnor S, Cano C, Baker DJ, Smith DM et al. ( 2020 ) . Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge . Diabetes, Obesity and Metabolism vol. 22 , ( 11 ) 1985 - 1994 .
Amor S, Fernández Blanco L, Baker D ( 2020 ) . Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage . Clinical and Experimental Immunology vol. 202 , ( 2 ) 193 - 209 .
Petrova N, Nutma E, Carassiti D, RS Newman J, Amor S, Altmann DR, Baker D, Schmierer K ( 2020 ) . Synaptic Loss in Multiple Sclerosis Spinal Cord . Annals of Neurology vol. 88 , ( 3 ) 619 - 625 .
Jacobs B, Taylor T, Awad A, Baker D, Giovannoni G, Noyce A, Dobson R ( 2020 ) . Summary-data-based mendelian randomisation prioritises potential druggable targets for Multiple Sclerosis . Brain Communications
Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al. ( 2020 ) . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases . Clinical and Experimental Immunology vol. 202 , ( 2 ) 149 - 161 .
Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,
Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G ( 2020 ) . The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic . Multiple Sclerosis and Related Disorders vol. 43 ,
Schmierer K, Baker D ( 2020 ) . B cells and multiple sclerosis spinal cord pathology . Brain Pathology vol. 30 , ( 4 ) 730 - 731 .
Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al. ( 2020 ) . Detecting and predicting neutralization of alemtuzumab responses in MS . Neurology(R) neuroimmunology & neuroinflammation vol. 7 , ( 4 )
Baker D ( 2020 ) . Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis . Acta Neuropathologica
Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G ( 2020 ) . SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad . Annals of Neurology vol. 87 , ( 6 ) 794 - 797 .
Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders Article 102279 , 102279 - 102279 .
Bertrand JA, Schicht M, Stamer WD, Baker D, Sherwood JM, Lütjen-Drecoll E, Selwood DL, Overby DR ( 2020 ) . The beta(4)-Subunit of the Large-Conductance Potassium Ion Channel K(Ca)1.1 Regulates Outflow Facility in Mice . Investigative Ophthalmology and Visual Science vol. 61 , ( 3 )
Ali L, SAXENA G, Jones M, Leisegang G, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K et al. ( 2020 ) . A cell-based assay for the detection of neutralizing antibodies against alemtuzumab . BioTechniques: the journal of laboratory technology for bioresearch
Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al. ( 2020 ) . The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies . Frontiers in Immunology vol. 11 , ( 124 )
Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al. ( 2020 ) . GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains . Scientific Reports vol. 10 , ( 1 ) Article 1860 ,
Baker D, Pryce G, James LK, Schmierer K, Giovannoni G ( 2020 ) . Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis . European Journal of Neurology vol. 27 , ( 2 ) 221 - 228 .
Farrell R, Baker D ( 2019 ) . An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity . Advances in Clinical Neuroscience and Rehabilitation vol. 18 , ( 5 ) 17 - 19 .
Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G ( 2019 ) . Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 35 , 19 - 25 .
Tabatabaee S, Baker D, Selwood DL, Whalley BJ, Stephens GJ ( 2019 ) . The cannabinoid-like compound, vsn16r, acts on large conductance, ca<sup>2</sup>+-activated k<sup>+</sup> channels to modulate hippocampal ca1 pyramidal neuron firing . Pharmaceuticals vol. 12 , ( 3 )
Baker D, Amor S ( 2019 ) . Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model . Annals of Clinical and Translational Neurology
Batcheller L, Baker D ( 2019 ) . Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer? . Journal of the Neurological Sciences vol. 404 , 19 - 28 .
Baker D, Pryce G, Herrod SS, Schmierer K ( 2019 ) . Potential mechanisms of action related to the efficacy and safety of cladribine . Multiple Sclerosis and Related Disorders vol. 30 , 176 - 186 .
Pryce G, Baker D ( 2019 ) . CHAPTER 11 Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . Emerging Drugs and Targets for Multiple Sclerosis ,
Pryce G, Baker D ( 2019 ) . CHAPTER 11: Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . RSC Drug Discovery Series , vol. 2019-January ,
Iegre J, Brear P, Baker DJ, Tan YS, Atkinson EL, Sore HF, O'Donovan DH, Verma CS et al. ( 2019 ) . Efficient development of stable and highly functionalised peptides targeting the CK2α/CK2β protein-protein interaction . Chemical Science vol. 10 , ( 19 ) 5056 - 5063 .
Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2019 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .
Nicholson T, Church C, Tsintzas K, Jones R, Breen L, Davis ET, Baker DJ, Jones SW ( 2019 ) . Vaspin promotes insulin sensitivity in elderly muscle and is upregulated in obesity . Journal of Endocrinology vol. 241 , ( 1 ) 31 - 43 .
Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G ( 2018 ) . Inclusion criteria used in trials of people with progressive multiple sclerosis . Mult Scler1352458518803769 - 1352458518803769 .
De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n > 200) - four years experience in clinical care .
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 949 - 949 .
BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K ( 2018 ) . Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis . Brain
BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D ( 2018 ) . Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss . Glia vol. 66 , ( 10 ) 2108 - 2125 .
Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .
BAKER D, Pryce, G ( 2018 ) . Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? . multiple sclerosis and related disorders
Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K ( 2018 ) . Cladribine: Mechanisms and mysteries in multiple sclerosis . Journal of Neurology, Neurosurgery and Psychiatry
Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al. ( 2018 ) . Alemtuzumab depletion failure can occur in multiple sclerosis . Immunology vol. 154 , ( 2 ) 253 - 260 .
Nicholson T, Church C, Baker DJ, Jones SW ( 2018 ) . The role of adipokines in skeletal muscle inflammation and insulin sensitivity . Journal of Inflammation (United Kingdom) vol. 15 , ( 1 )
Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K ( 2018 ) . Axonal loss in the multiple sclerosis spinal cord revisited . Brain Pathology vol. 28 , ( 3 ) 334 - 348 .
Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al. ( 2018 ) . Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells . Journal of Neurology vol. 265 , ( 5 ) 1199 - 1209 .
Ceronie B, Dubuisson N, Ammoscato F, Baker D, Giovannoni G, Schmierer K ( 2018 ) . Memory B Cells: Toward a Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis . NEUROLOGY . vol. 90 ,
Ruz-Maldonado I, Liu B, Atanes P, Pingitore A, Huang GC, Baker D, Persaud SJ ( 2018 ) . CB1 antagonists SR141617A and AM251 stimulate insulin secretion from mouse and human islets . DIABETIC MEDICINE . vol. 35 , 47 - 47 .
Biggs EK, Liang L, Naylor J, Madalli S, Collier R, Coghlan MP, Baker DJ, Hornigold DC et al. ( 2018 ) . Development and characterisation of a novel glucagon like peptide-1 receptor antibody . Diabetologia vol. 61 , ( 3 ) 711 - 721 .
Conway LC, Cardarelli RA, Moore YE, Jones K, McWilliams LJ, Baker DJ, Burnham MP, Bürli RW et al. ( 2017 ) . N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation . Journal of Biological Chemistry vol. 292 , ( 52 ) 21253 - 21263 .
Ruz-Maldonado I, Pingitore A, Liu B, Atanes P, Huang GC, Baker D, Alonso FJ, Bermúdez-Silva FJ et al. ( 2017 ) . LH‐21 and abnormal cannabidiol improve β‐cell function in isolated human and mouse islets through GPR55‐dependent and ‐independent signalling . Diabetes Obes Metab vol. 20 , ( 4 ) 930 - 942 .
Ouberai MM, Dos Santos ALG, Kinna S, Madalli S, Hornigold DC, Baker D, Naylor J, Sheldrake L et al. ( 2017 ) . Controlling the bioactivity of a peptide hormone in vivo by reversible self-assembly . Nature Communications vol. 8 , ( 1 )
Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K ( 2017 ) . Disease modification in advanced MS: Focus on upper limb function . Multiple Sclerosis vol. 23 , ( 14 ) 1956 - 1957 .
Will S, Hornigold DC, Baker DJ, Coghlan MP, Mesquita M, Trevaskis JL, Naylor J ( 2017 ) . Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity . Current Opinion in Pharmacology vol. 37 , 10 - 15 .
Agez M, Schultz P, Medina I, Baker DJ, Burnham MP, Cardarelli RA, Conway LC, Garnier K et al. ( 2017 ) . Molecular architecture of potassium chloride co-transporter KCC2 . Scientific Reports vol. 7 , ( 1 )
Puentes F, van der Star BJ, Boomkamp SD, Kipp M, Boon L, Bosca I, Raffel J, Gnanapavan S et al. ( 2017 ) . Neurofilament light as an immune target for pathogenic antibodies . Immunology vol. 152 , ( 4 ) 580 - 588 .
Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. ( 2017 ) . PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,
Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D ( 2017 ) . PO150 Memory b cells are key for immunotherapy in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 , a52 - a52 .
Pryce G, Baker D ( 2017 ) . Antidote to cannabinoid intoxication: the CB<inf>1</inf> receptor inverse agonist, AM251, reverses hypothermic effects of the CB<inf>1</inf> receptor agonist, CB-13, in mice . British Journal of Pharmacology vol. 174 , ( 21 ) 3790 - 3794 .
Baker D, Giovannoni G, Schmierer K ( 2017 ) . Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment . Multiple Sclerosis and Related Disorders
Baker D, Kang AS, Gnanapavan S, Giovannoni G, Schmierer K ( 2017 ) . A central role of B cells in MS control and causing autoimmunity after alemtuzumab . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 336 - 336 .
Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al. ( 2017 ) . Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Multiple Sclerosis and Related Disorders vol. 17 , 172 - 176 .
BAKER D ( 2017 ) . SPATIAL DISTRIBUTION OF THE CANNABINOID TYPE 1 AND CAPSAICIN RECEPTORS MAY CONTRIBUTE TO THE COMPLEXITY OF THEIR CROSSTALK . Scientific Reports
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may affect MS via B-cell depletion (vol 4, e360, 2017) . NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION vol. 4 , ( 5 )
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K ( 2017 ) . Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab . JAMA Neurol vol. 74 , ( 8 ) 961 - 969 .
Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K ( 2017 ) . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis . Mult Scler1352458517726380 - 1352458517726380 .
BAKER D ( 2017 ) . Big conductance calcium-activated potassium channel openers control spasticity without sedation . British Journal of Pharmcology
BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C ( 2017 ) . Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion . Neurology: Neuroimmunology and Neuroinflammation vol. 4 , ( 4 )
Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K ( 2017 ) . Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis . Annals of Clinical and Translational Neurology
BAKER D, Giovannoni G, Sefia E, Pryce G, Meier U ( 2017 ) . Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis . Multiple Sclerosis and Related Disorders
Schmierer K, Herrod S, Alvarez-Gonzalez C, Baker D ( 2017 ) . Cladribine versus Alemtuzumab: efficacy and autoimmunity in multiple sclerosis induction treatment . NEUROLOGY . vol. 88 ,
Thomson A, Raciborska D, Baker D, Giovannoni G ( 2017 ) . How to start a blog . Pract Neurol vol. 17 , ( 3 ) 224 - 228 .
Herrera M, Söderberg M, Sabirsh A, Valastro B, Mölne J, Santamaria B, Valverde AM, Guionaud S et al. ( 2017 ) . Inhibition of T-Cell activation by the CTLA4-Fc abatacept is sufficient to ameliorate proteinuric kidney disease . American Journal of Physiology - Renal Physiology vol. 312 , ( 4 ) F748 - F759 .
von Kutzleben S, Pryce G, Giovannoni G, Baker D ( 2017 ) . Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immunetolerance promoting CD8 t-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis . Immunology vol. 150 , ( 4 ) 444 - 455 .
Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K ( 2017 ) . Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis . EBioMedicine vol. 16 , 41 - 50 .
Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al. ( 2017 ) . Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses . Multiple Sclerosis and Related Disorders vol. 12 , 70 - 78 .
Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may effect MS via B-cell depletion . Neurology: Neuroimmunology and NeuroInflammation vol. 4 , ( 4 )
Cardarelli RA, Jones K, Pisella LI, Wobst HJ, McWilliams LJ, Sharpe PM, Burnham MP, Baker DJ et al. ( 2017 ) . The small molecule CLP257 does not modify activity of the K <sup>+</sup> -Cl <sup>-</sup> co-transporter KCC2 but does potentiate GABA <inf>A</inf> receptor activity . Nature Medicine vol. 23 , ( 12 ) 1394 - 1396 .
Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ ( 2016 ) . GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans . Diabetes, Obesity and Metabolism vol. 18 , ( 12 ) 1263 - 1273 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87 ,
Williams T, Pryce G, Giovannoni G, Selwood D, Baker D ( 2016 ) . VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS . vol. 87 , is. 12 , Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,
Baker D, Anandhakrishnan A, Tuite-Dalton KA, Lockart¿Jones H, Middleton RM, Ford DV, Crowe C, Giovannoni G ( 2016 ) . How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 10 , 127 - 133 .
Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al. ( 2016 ) . Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice . Immunology vol. 149 , ( 2 ) 146 - 156 .
Agahozo MC, Peferoen L, Baker D, Amor S ( 2016 ) . CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis – Targeting T or B cells? . Multiple Sclerosis and Related Disorders vol. 9 , Article C , 110 - 117 .
Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K ( 2016 ) . Importance of upper limb function in advanced multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 676 - 676 .
Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z ( 2016 ) . Induction therapy of relapsing secondary multiple sclerosis using generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 593 - 594 .
Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K ( 2016 ) . Synaptic loss in the MS spinal cord: a key driver of disease progression? . MULTIPLE SCLEROSIS JOURNAL . Conference: ECTRIMS 2016 Committees ( UCL Institute of Neurology, London, UK ) from: 14/09/2016 to: 17/09/2016 , vol. 22 , 80 - 80 .
Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . Treating multiple sclerosis with generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22 , 604 - 605 .
Sevastou I, Pryce G, Baker D, Selwood DL ( 2016 ) . Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing . PLOS ONE vol. 11 , ( 6 ) e0157754 - e0157754 .
Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al. ( 2016 ) . Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease . European Journal of Immunology vol. 46 , ( 3 ) 701 - 711 .
Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al. ( 2016 ) . Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis . Journal of Biological Chemistry vol. 291 , ( 9 ) 4356 - 4373 .
Naylor J, Suckow AT, Seth A, Baker DJ, Sermadiras I, Ravn P, Howes R, Li J et al. ( 2016 ) . Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP- 1R agonists . Biochemical Journal vol. 473 , ( 18 ) 2881 - 2891 .
Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D ( 2015 ) . Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids . Journal of Neuroimmune Pharmacology vol. 10 , ( 2 ) 281 - 292 .
Pryce G, Baker D ( 2015 ) . Endocannabinoids in multiple sclerosis and amyotrophic lateral sclerosis . vol. 231 , 213 - 231 .
Ruz Maldonado I, Pingitore A, Liu B, Huang GC, Baker D, Bermudez-Silva FJ, Persaud SJ ( 2015 ) . Stimulation of insulin secretion by cannabinoid ligands LH-21 and Abn-CBD in mouse and human islets: evaluation of the role of GPR55 . DIABETOLOGIA . vol. 58 , S86 - S86 .
Pryce G, Baker D ( 2015 ) . Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis . Evidence-Based Medicine vol. 20 , ( 4 )
Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. ( 2015 ) . Microglia are involved in apoptotic clearance during chronic-relapsing EAE . GLIA . vol. 63 , E353 - E353 .
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical and Experimental Immunology vol. 180 , ( 3 ) 432 - 441 .
Waring MJ, Baker DJ, Bennett SNL, Dossetter AG, Fenwick M, Garcia R, Georgsson J, Groombridge SD et al. ( 2015 ) . Discovery of a series of 2-(pyridinyl)pyrimidines as potent antagonists of GPR40 . MedChemComm vol. 6 , ( 6 ) 1024 - 1029 .
Baker D, Amora S ( 2015 ) . Mouse models of multiple sclerosis: Lost in translation? . Current Pharmaceutical Design vol. 21 , ( 18 ) 2440 - 2452 .
Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2015 ) . Correction to Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis . J Med Chem vol. 58 , ( 8 )
Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S ( 2015 ) . Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy . Biosensors and Bioelectronics vol. 68 , 660 - 667 .
Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al. ( 2015 ) . Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation . Journal of Cerebral Blood Flow and Metabolism vol. 35 , ( 3 ) 412 - 423 .
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical and Experimental Immunology
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al. ( 2015 ) . No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine . Neurology: Neuroimmunology and NeuroInflammation vol. 2 , ( 6 )
Giovannoni G, Baker D, Schmierer K ( 2015 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 1 ) 3 - 5 .
Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D ( 2014 ) . Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody . Journal of Neuroimmunology . vol. 275 ,
Giovannoni G, Baker D, Schmierer K ( 2014 ) . Simvastatin in patients with progressive multiple sclerosis . Lancet vol. 384 , ( 9947 )
Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. ( 2014 ) . CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .
Pakpoor J, Nyein S, Disanto G, Nwosu A, Baker D, Giovannoni G ( 2014 ) . A global analysis of the use of social media to discuss multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 334 - 335 .
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . Knockout of GPR55 impairs insulin secretion and reduces islet cell turnover . DIABETOLOGIA vol. 57 , S49 - S49 .
Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al. ( 2014 ) . Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis . Mult Scler vol. 20 , ( 10 ) 1355 - 1362 .
Giovannoni G, Baker D, Schmierer K ( 2014 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al. ( 2014 ) . MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation . FASEB J vol. 28 , ( 6 ) 2551 - 2565 .
Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2014 ) . Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis . J Med Chem vol. 57 , ( 7 ) 2942 - 2952 .
Baker DJ, Atkinson AM, Wilkinson GP, Coope GJ, Charles AD, Leighton B ( 2014 ) . Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1629 - 1641 .
Baker DJ, Wilkinson GP, Atkinson AM, Jones HB, Coghlan M, Charles AD, Leighton B ( 2014 ) . Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1642 - 1654 .
Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . GPR55 deletion is coupled to impaired insulin secretion and reduced islet cell turnover . DIABETIC MEDICINE vol. 31 , 9 - 9 .
Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al. ( 2014 ) . Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis . J Neurol Neurosurg Psychiatry vol. 85 , ( 3 ) 274 - 278 .
Song S, Liu B, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2014 ) . Specificity of GPR55 agonists and antagonist in the regulation of calcium handling and insulin secretion by mouse islets . DIABETIC MEDICINE vol. 31 , 32 - 32 .
Van Den Elsen PJ, Van Eggermond MCJA, Puentes F, Van Der Valk P, Baker D, Amor S ( 2014 ) . The epigenetics of multiple sclerosis and other related disorders . Multiple Sclerosis and Related Disorders vol. 3 , ( 2 ) 163 - 175 .
Dua P, Warnes G, Chruch A, Martino D, Baker D, Giovannoni G, Meier UC ( 2014 ) . Functional effects of anti-neuronal antibodies from patients with Tourette's syndrome and disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 20 , ( 1 ) 17 - 18 .
Whyte L, Khalid A, Finnie G, Chiu S, Baker D, Aspden R, Ross R ( 2014 ) . GPR55 Regulates Peak Bone Mass and Steroid Hormone Levels in Male Mice . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 29 , S409 - S409 .
Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJM, Giovannoni G, Baker D, Chandran S ( 2014 ) . Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis . Acta Neuropathologica Communications vol. 2 , ( 1 )
Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al. ( 2014 ) . Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists . FASEB J vol. 28 , ( 1 ) 117 - 130 .
Baker D, Amor S ( 2014 ) . Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely . Multiple Sclerosis and Related Disorders
Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D, Van Noort JM ( 2014 ) . Inflammation in neurodegenerative diseases - an update . Immunology vol. 142 , ( 2 ) 151 - 166 .
Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al. ( 2014 ) . Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β . Expert Opin Drug Deliv vol. 11 , ( 1 ) 5 - 16 .
Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, Rigby A, Sclanders M et al. ( 2014 ) . Latent cytokines for targeted therapy of inflammatory disorders . Expert Opin Drug Deliv vol. 11 , ( 1 ) 101 - 110 .
Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al. ( 2014 ) . Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis . Brain vol. 137 , ( Pt 1 ) 92 - 108 .
Baker D, Pepper G, Yauner F, Giovannoni G ( 2014 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 3 , ( 1 ) 31 - 33 .
Baker D, Lidster K, Sottomayor A, Amor S ( 2014 ) . Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies . PLoS Biol vol. 12 , ( 1 )
Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al. ( 2013 ) . Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors . Mult Scler vol. 19 , ( 14 ) 1896 - 1904 .
Delarasse C, Smith P, Baker D, Amor S ( 2013 ) . Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice . Immunology vol. 140 , ( 4 ) 456 - 464 .
James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV ( 2013 ) . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis . Mult Scler vol. 19 , ( 12 ) 1571 - 1579 .
Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al. ( 2013 ) . Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis . Journal of Neuroinflammation vol. 10 ,
Liu B, Song S, Baker D, Bowe J, Hassan Z, Drynda R, Jones P, Persaud S ( 2013 ) . GPR55 deletion is coupled to impaired glucose tolerance and increased islet cell apoptosis . DIABETOLOGIA . vol. 56 , S46 - S46 .
Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampa C, Costa C, Tantucci M et al. ( 2013 ) . Effects of central and peripheral inflammation on hippocampal synaptic plasticity . NEUROBIOLOGY OF DISEASE vol. 52 , 229 - 236 .
Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G ( 2013 ) . Animal models of progressive disability in MS . IRISH JOURNAL OF MEDICAL SCIENCE vol. 182 , S5 - S6 .
Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al. ( 2013 ) . Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis . PLoS One vol. 8 , ( 10 )
Baker D, Pepper G, Yauner F, Giovannoni G ( 2013 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders
Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D ( 2013 ) . Neuroprotection in a novel mouse model of multiple sclerosis . PLoS One vol. 8 , ( 11 )
van den Elsen PJ, van Eggermond MCJA, Puentes F, van der Valk P, Baker D, Amor S ( 2013 ) . The epigenetics of multiple sclerosis and other related disorders . Multiple Sclerosis and Related Disorders
Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. ( 2012 ) . Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 3 - 4 .
van der Star B, Puentes F, Gerritsen W, Huizinga R, Reijerkerk A, van der Valk P, Baker D, Amor S ( 2012 ) . Neuronal specific T cells are pathogenic in Biozzi mice - Implications for MS . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 155 - 155 .
Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Reproducibility: Research-reporting standards fall short . Nature vol. 492 , ( 7427 )
Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Reproducibility: Research-reporting standards fall short . Nature vol. 492 , ( 7427 )
Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, Chandraratna D, Ciccarelli O et al. ( 2012 ) . Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS . MULTIPLE SCLEROSIS JOURNAL vol. 18 , ( 11 ) 1534 - 1540 .
Song S, Liu B, Baker D, Huang GC, Amiel SA, King AJ, Bowe JE, Jones PM et al. ( 2012 ) . Islet GPR55 is coupled to increased insulin secretion and decreased apoptosis . DIABETOLOGIA vol. 55 , S163 - S163 .
Li C, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2012 ) . PS 014 Beta cell GPCRs and other signalling mechanisms . DIABETOLOGIA vol. 55 , S163 - S163 .
van der Star BJ, Vogel DYS, Kipp M, Puentes F, Baker D, Amor S ( 2012 ) . In Vitro and In Vivo Models of Multiple Sclerosis . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 570 - 588 .
van Noort JM, Baker D, Amor S ( 2012 ) . Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 556 - 569 .
Baker D, Amor S ( 2012 ) . Multiple sclerosis - from bench to bedside . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 495 - 496 .
Lidster K, Baker D ( 2012 ) . Optical coherence tomography detection of neurodegeneration in multiple sclerosis . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 518 - 527 .
Pryce G, Baker D ( 2012 ) . Potential control of multiple sclerosis by cannabis and the endocannabinoid system . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 624 - 641 .
Amor S, Baker D ( 2012 ) . Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders . Multiple Sclerosis and Related Disorders vol. 1 , ( 3 ) 111 - 115 .
Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G ( 2012 ) . Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis . Autoimmunity vol. 45 , ( 4 ) 298 - 303 .
Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G ( 2012 ) . The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 1 , ( 2 ) 64 - 75 .
Dua P, Meier UC, Baker D, Giovannoni G ( 2012 ) . Functional effects of anti-neuronal antibodies in patients with encephalitis lethargica and other related disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 18 , ( 2 )
Baker D, Amor S ( 2012 ) . Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis . J Neuroimmunol vol. 242 , ( 1-2 ) 78 - 83 .
Kipp M, Van Der Star B, Vogel DYS, Puentes F, Van Der Valk P, Baker D, Amor S ( 2012 ) . Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 15 - 28 .
Sher F, Amor S, Gerritsen W, Baker D, Jackson SL, Boddeke E, Copray S ( 2012 ) . Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing-Remitting EAE in Mice . CELL TRANSPLANTATION vol. 21 , ( 9 ) 1883 - 1897 .
Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D ( 2012 ) . Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 29 - 38 .
Puentes F, van der Star B, Huizinga R, Gerritsen W, van der Valk P, Baker D, Amor S ( 2011 ) . Autoimmunity to axonal proteins in multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S329 - S329 .
Jackson S, Giovannoni G, Baker D ( 2011 ) . Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S210 - S210 .
Lidster K, Jackson S, Coffey P, Baker M, Garthwaite J, Selwood D, Giovannoni G, Baker D ( 2011 ) . Neuroprotection in a novel optic neuritis model . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S435 - S435 .
Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S209 - S210 .
Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of spasticity by CNS-excluded cannabinoids . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S247 - S247 .
Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al. ( 2011 ) . VSN16R a novel agent for the control of spasticity . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S243 - S243 .
Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D ( 2011 ) . Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404 . Drug Metab Dispos vol. 39 , ( 9 ) 1689 - 1695 .
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis . Mult Scler vol. 17 , ( 8 ) 939 - 948 .
Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Fingolimod modulates microglial activation to augment markers of remyelination . J Neuroinflammation vol. 8 ,
Andreou AP, Supronsinchai W, Lasalandra M, Baker D, Goadsby PJ ( 2011 ) . Cannabinoid mechanisms of acetaminophen within the trigeminal thalamus . CEPHALALGIA . vol. 31 , 8 - 8 .
Baker D, Gerritsen W, Rundle J, Amor S ( 2011 ) . Critical appraisal of animal models of multiple sclerosis . Mult Scler vol. 17 , ( 6 ) 647 - 657 .
Baker D, Amor S ( 2010 ) . Editorial: Quality control of experimental autoimmune encephalomyelitis . Multiple Sclerosis vol. 16 , ( 9 ) 1025 - 1027 .
Baker D, Amor S ( 2010 ) . Quality control of experimental autoimmune encephalomyelitis . Mult Scler vol. 16 , ( 9 ) 1025 - 1027 .
Amor S, Puentes F, Baker D, van der Valk P ( 2010 ) . Inflammation in neurodegenerative diseases . IMMUNOLOGY vol. 129 , ( 2 ) 154 - 169 .
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid Receptor Type 1 Protects against Age-Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells . CELL METAB vol. 10 , ( 2 ) 139 - 147 .
Al-Izki S, Pryce G, Giovannoni G, Baker D ( 2009 ) . Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography . Mult Scler vol. 15 , ( 7 ) 795 - 801 .
Idris AI, Sophocleous A, Landao-Bassonga E, Merkouris M, Milligan GI, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells . BONE . vol. 44 , S222 - S222 .
Hooper C, Pinteaux-Jones F, Fry VA, Sevastou IG, BAKER D, Heales SJ, Pocock JM ( 2009 ) . Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage . J Neurochem vol. 109 , ( 3 ) 694 - 705 .
Rigby A, Baker D, Chernajovsky Y ( 2008 ) . Targeting EPO to the CNS; development of a novel therapeutic strategy . IMMUNOLOGY . vol. 125 , 134 - 135 .
Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al. ( 2008 ) . An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss . J NEUROIMMUNOL vol. 201 , 200 - 211 .
Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D ( 2008 ) . Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 14 , S80 - S81 .
Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K ( 2008 ) . High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis . MULTIPLE SCLEROSIS . vol. 14 , S86 - S87 .
Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D ( 2008 ) . Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 173 - 173 .
Rigby A, Chernajovsky Y, Baker D ( 2008 ) . Targeting EPO to the CNS; Development of a novel therapeutic strategy . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 171 - 171 .
Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al. ( 2008 ) . Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis . BRAIN vol. 131 , 1736 - 1748 .
Pinteaux-Jones F, Sevastou IG, Fry VAH, Heales S, Baker D, Pocock JM ( 2008 ) . Myelin-induced microglial neurotoxicity can be controlled by microglial metabotropic glutamate receptors . J NEUROCHEM vol. 106 , ( 1 ) 442 - 454 .
East E, Gveri¿ D, Baker D, Pryce G, Lijnen HR, Cuzner ML ( 2008 ) . Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation . Neuropathol Appl Neurobiol vol. 34 , ( 2 ) 216 - 230 .
Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D ( 2008 ) . Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis . J NEUROIMMUNOL vol. 193 , ( 1-2 ) 120 - 129 .
Pryce G, Jackson SJ, Baker D ( 2008 ) . Cannabinoids for the control of multiple sclerosis . Cannabinoids and the Brain ,
Baker D, Pryce G ( 2008 ) . The endocannabinoid system and multiple sclerosis . Curr Pharm Des vol. 14 , ( 23 ) 2326 - 2336 .
Baker D, Jackson SJ, Pryce G ( 2007 ) . Cannabinoid control of neuroinflammation related to multiple sclerosis . BRIT J PHARMACOL vol. 152 , ( 5 ) 649 - 654 .
Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, Baker D, Selwood DL et al. ( 2007 ) . Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide (VSN16) in the rat . BRIT J PHARMACOL vol. 152 , ( 5 ) 751 - 764 .
Pocock JM, Pinteaux-Jones F, Fry VA, Baker D, Heales SJ ( 2007 ) . Metabotropic glutamate receptors on microglia: Switching off toxicity . JOURNAL OF NEUROCHEMISTRY . vol. 102 , 239 - 239 .
Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al. ( 2007 ) . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells . NAT MED vol. 13 , ( 4 ) 492 - 497 .
Pryce G, Baker D ( 2007 ) . Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors . BRIT J PHARMACOL vol. 150 , ( 4 ) 519 - 525 .
Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 90 - 91 .
Baker D ( 2006 ) . Protection of axonal damage in experimental antoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 12 , S12 - S13 .
Baker D ( 2006 ) . Role of immunity in neurodegeneration in autoimmune encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 20 - 20 .
Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J ( 2006 ) . Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice . BRAIN RES vol. 1107 , 199 - 205 .
Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L ( 2006 ) . Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice . FASEB J vol. 20 , ( 7 ) 1003 - + .
Baker D, Pryce G, Croxford JL, Yamamura T ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits . CURRENT TOPICS IN NEUROIMMUNOLOGY . Editors: Tabira, T, Yamamura, T, Kira, J , 109 - 116 .
Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V ( 2006 ) . Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain . NEUROSCIENCE vol. 139 , ( 4 ) 1405 - 1415 .
Baker D, Pryce G, Davies WL, Hiley CR ( 2006 ) . In silico patent searching reveals a new cannabinoid receptor . TRENDS PHARMACOL SCI vol. 27 , ( 1 ) 1 - 4 .
Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al. ( 2006 ) . New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis . BRIT J PHARMACOL vol. 147 , ( 1 ) 83 - 91 .
de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA ( 2006 ) . UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders . EUR NEUROPSYCHOPHARM vol. 16 , ( 1 ) 7 - 18 .
Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S ( 2005 ) . Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice . J NEUROIMMUNOL vol. 167 , ( 1-2 ) 23 - 33 .
East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gveri¿ D ( 2005 ) . A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis . Am J Pathol vol. 167 , ( 2 ) 545 - 554 .
Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D ( 2005 ) . Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 41 - 52 .
Amor S, Smith PA, 't Hart B, Baker D ( 2005 ) . Biozzi mice: Of mice and human neurological diseases . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 1 - 10 .
Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al. ( 2005 ) . Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice . J NEUROIMMUNOL vol. 164 , ( 1-2 ) 76 - 84 .
Idris AI, Hof RJV, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors . NAT MED vol. 11 , ( 7 ) 774 - 779 .
Jackson SJ, Diemel LT, Pryce G, Baker D ( 2005 ) . Cannabinoids and neuroprotection in CNS inflammatory disease . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 233 , 21 - 25 .
Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss . BONE . vol. 36 , S132 - S132 .
Pryce G, Baker D ( 2005 ) . Emerging properties of cannabinoid medicines in management of multiple sclerosis . TRENDS NEUROSCI vol. 28 , ( 5 ) 272 - 276 .
Visintin C, Aliev AE, Riddall D, Baker D, Okuyama M, Hoi PM, Hiley R, Selwood DL ( 2005 ) . Membrane receptor probes: Solid-phase synthesis of biotin-Asp-PEG-arvanil derivatives . ORG LETT vol. 7 , ( 9 ) 1699 - 1702 .
Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al. ( 2005 ) . Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction . J IMMUNOL vol. 174 , ( 4 ) 2327 - 2335 .
Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D ( 2005 ) . Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation . NEUROSCIENCE vol. 134 , ( 1 ) 261 - 268 .
Constantinescu CS, Baker D ( 2005 ) . Cytokines in experimental autoimmune encephalomyelitis . Experimental Models of Multiple Sclerosis ,
Baker D ( 2005 ) . Genetics of experimental allergic encephalomyelitis . Experimental Models of Multiple Sclerosis ,
Jackson SJ, Baker D, Cuzner ML, Diemel LT ( 2004 ) . Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture . EUR J NEUROSCI vol. 20 , ( 9 ) 2267 - 2275 .
Idris AI, Van't Hof' RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2004 ) . Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 19 , S284 - S284 .
Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D ( 2004 ) . Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 78 - 78 .
Heijmans N, Smith P, Pryce D, Baker D, Morris-Downes M, Amor S ( 2004 ) . Non-encephalitogenic single amino acid substitutions of MOG 8-21 and PLP 56-70 suppress relapsing EAE in ABH mice . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 60 - 60 .
Baker D, Pryce G ( 2004 ) . The potential role of the endocannabinoid system in the control of multiple scleorsis . Current Medicinal Chemistry - Central Nervous System Agents vol. 4 , ( 3 ) 195 - 202 .
East E, Baker D, Pryce G, Cuzner ML, Gveric D ( 2004 ) . The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 167 - 167 .
Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boyton RJ, Smith PA, Amor S et al. ( 2004 ) . Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis . EUR J IMMUNOL vol. 34 , ( 7 ) 1839 - 1848 .
de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al. ( 2004 ) . In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake . EUR J PHARMACOL vol. 484 , ( 2-3 ) 249 - 257 .
Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM ( 2003 ) . Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects? . J PHARM PHARMACOL vol. 55 , ( 12 ) 1687 - 1694 .
Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al. ( 2003 ) . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis . BRAIN vol. 126 , 2191 - 2202 .
Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG ( 2003 ) . Temporal course of upregulation of Na-v 1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis . J NEUROPATH EXP NEUR vol. 62 , ( 9 ) 968 - 975 .
East E, Baker D, Pryce GM, Cuzner ML, Gveric D ( 2003 ) . The role of plasminogen activators in experimental allergic encephalomyelitis . GLIA . 40 - 40 .
Ahmed Z, Baker D, Cuzner ML ( 2003 ) . Interleukin-12 induces mild experimental allergic encephalomyelitis following local central nervous system injury in the Lewis rat . J NEUROIMMUNOL vol. 140 , ( 1-2 ) 109 - 117 .
Giovannoni G, Baker D ( 2003 ) . Inflammatory disorders of the central nervous system . CURR OPIN NEUROL vol. 16 , ( 3 ) 347 - 350 .
Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR ( 2003 ) . An autoimmune diabetes locus (Idd21) on mouse Chromosome 18 . MAMM GENOME vol. 14 , ( 5 ) 335 - 339 .
Baker D, Hankey DJR ( 2003 ) . Gene therapy in autoimmune, demyelinating disease of the central nervous system . GENE THER vol. 10 , ( 10 ) 844 - 853 .
Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P ( 2003 ) . Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis . FASEB J vol. 17 , ( 8 ) 905 - 907 .
Pryce G, Giovannoni G, Baker D ( 2003 ) . Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice . NEUROSCI LETT vol. 341 , ( 2 ) 164 - 166 .
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G ( 2003 ) . Quantification of neurodegeneration by measurement of brain-specific proteins . J NEUROIMMUNOL vol. 138 , ( 1-2 ) 45 - 48 .
Baker D, Pryce G, Giovannoni G, Thompson AJ ( 2003 ) . The therapeutic potential of cannabis . LANCET NEUROL vol. 2 , ( 5 ) 291 - 298 .
Baker D, Pryce G ( 2003 ) . The therapeutic potential of cannabis in multiple sclerosis . EXPERT OPIN INV DRUG vol. 12 , ( 4 ) 561 - 567 .
Craner MJ, Lo AC, Black JA, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2003 ) . Annexin II/piII is up-regulated in Purkinje cells in EAE and MS . NEUROREPORT vol. 14 , ( 4 ) 555 - 558 .
Baker D, Adamson P, Greenwood J ( 2003 ) . Potential of statins for the treatment of multiple sclerosis . LANCET NEUROL vol. 2 , ( 1 ) 9 - 10 .
Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML ( 2002 ) . A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration . AM J PATHOL vol. 161 , ( 5 ) 1577 - 1586 .
Hall RJ, Hollis-Moffat JE, Merriman ME, Bridges RJ, Green RA, Williams G, Baker D, Merriman TR ( 2002 ) . An autoimmune diabetes locus (ldd21) on mouse chromosome 18 . AMERICAN JOURNAL OF HUMAN GENETICS . vol. 71 , 446 - 446 .
Thompson AJ, Baker D ( 2002 ) . Cannabinoids in MS - Potentially useful but not just yet! . NEUROLOGY vol. 58 , ( 9 ) 1323 - 1324 .
Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P ( 2002 ) . Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis . J IMMUNOL vol. 168 , ( 8 ) 4087 - 4094 .
Morris-Downes MM, Smith PA, Rundle JL, Piddlesden SJ, Baker D, Pham-Dinh D, Heijmans N, Amor S ( 2002 ) . Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice . J NEUROIMMUNOL vol. 125 , ( 1-2 ) 114 - 124 .
Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G ( 2002 ) . The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT)dagger . EUR J VASC ENDOVASC vol. 23 , ( 4 ) 358 - 364 .
Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al. ( 2002 ) . Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors . EUR J PHARMACOL vol. 439 , ( 1-3 ) 83 - 92 .
Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S ( 2002 ) . Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) in ABH and SJL mice . J NEUROIMMUNOL vol. 122 , ( 1-2 ) 20 - 33 .
Hankey DJR, Nickerson JM, Donoso LA, Lightman SL, Baker D ( 2001 ) . Experimental autoimmune uveoretinitis in mice (Biozzi ABH and NOD) expressing the autoimmune-associated H-2A(g7) molecule: identification of a uveitogenic epitope . J NEUROIMMUNOL vol. 118 , ( 2 ) 212 - 222 .
Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT ( 2001 ) . Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat . Am J Pathol vol. 158 , ( 6 ) 2127 - 2138 .
Croxford JL, Feldmann M, Chernajovsky Y, Baker D ( 2001 ) . Different therapeutic outcomes in experimental allergic encephalomyelitis dependant upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system . J IMMUNOL vol. 166 , ( 6 ) 4124 - 4130 .
Reichel MB, Bainbridge J, Baker D, Thrasher AJ, Bhattacharya SS, Ali RR ( 2001 ) . An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse . BRIT J OPHTHALMOL vol. 85 , ( 3 ) 341 - 344 .
Hankey DJR, Lightman SL, Baker D ( 2001 ) . Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: Characterization of disease parameters and immunomodulation . EXP EYE RES vol. 72 , ( 3 ) 341 - 350 .
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al. ( 2001 ) . Endocannabinoids control spasticity in a multiple sclerosis model . FASEB J vol. 15 , ( 2 ) 300 - 302 .
Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2000 ) . Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis . Proceedings of the National Academy of Sciences of the United States of America vol. 97 , ( 21 ) 11598 - 11602 .
Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford JL, Baker D et al. ( 2000 ) . Immuno- and genetic therapy in autoimmune diseases . Genes Immun vol. 1 , ( 5 ) 295 - 307 .
Baker D ( 2000 ) . Reply: a sanguine approach to cannabis . Trends Pharmacol Sci vol. 21 , ( 6 )
Thoua NM, van Noort JM, Baker D, Bose A, van Sechel AC, van Stipdonk MJB, Travers PJ, Amor S ( 2000 ) . Encephalitogenic and immunogenic potential of the stress protein alpha B-crystallin in Biozzi ABH (H-2A(g7)) mice . JOURNAL OF NEUROIMMUNOLOGY vol. 104 , ( 1 ) 47 - 57 .
Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L ( 2000 ) . Cannabinoids control spasticity and tremor in a multiple sclerosis model . Nature vol. 404 , ( 6773 ) 84 - 87 .
Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D ( 2000 ) . Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor . J Immunol vol. 164 , ( 5 ) 2776 - 2781 .
Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al. ( 1999 ) . Immunotherapy of auto-immune diseases by gene transfer . Biochem Soc Trans vol. 27 , ( 6 ) 869 - 873 .
Brennan FR, O'Neill JK, Allen SJ, Butter C, Nuki G, Baker D ( 1999 ) . CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease . Immunology vol. 98 , ( 3 ) 427 - 435 .
Croxford JL, O'Neill JK, Ali RR, Browne K, Byrnes AP, Dallman MJ, Wood MJ, Fedlmann M et al. ( 1998 ) . Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis . Eur J Immunol vol. 28 , ( 12 ) 3904 - 3916 .
Ali RR, Reichel MB, Byrnes AP, Stephens CJ, Thrasher AJ, Baker D, Hunt DM, Bhattacharya SS ( 1998 ) . Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina . GENE THERAPY vol. 5 , ( 11 ) 1561 - 1565 .
Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y ( 1998 ) . Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system . J Immunol vol. 160 , ( 10 ) 5181 - 5187 .
O'Neill JK, Baker D, Morris MM, Gschmeissner SE, Jenkins HG, Butt AM, Kirvell SL, Amor S ( 1998 ) . Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: Demyelination and fast axonal transport changes in disease . JOURNAL OF NEUROIMMUNOLOGY vol. 82 , ( 2 ) 210 - 218 .
Chernajovsky Y, Annenkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, Moyes SP, Croxford JL et al. ( 1998 ) . Gene therapy for rheumatoid arthritis. Theoretical considerations . Drugs and Aging vol. 12 , ( 1 ) 29 - 41 .
Triantaphyllopoulos KA, Croxford JL, Baker D, Chernajovsky Y ( 1998 ) . Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis . Gene Therapy vol. 5 , ( 2 ) 253 - 263 .
Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D ( 1998 ) . Immune responses limit adenovirally mediated gene expression in the adult mouse eye . Gene Therapy vol. 5 , ( 8 ) 1038 - 1046 .
Reichet MB, All RR, Baker D, Byrnes AP, D'Esposito F, Kanuga N, Hunt DM, Bhattacharya SS ( 1997 ) . Co-injection of adenovirus expressing CTLA4-IG prolongs adenovirally-mediated lacz reporter gene expression in the mouse retina . Investigative Ophthalmology and Visual Science vol. 38 , ( 4 )
Croxford JL, O'Neill JK, Baker D ( 1997 ) . Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice . J Neuroimmunol vol. 74 , ( 1-2 ) 205 - 211 .
Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S ( 1997 ) . Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection . Journal of Neuroimmunology vol. 74 , ( 1-2 ) 185 - 197 .
Amor S, Baker D, Layward L, McCormack K, Van Noort JM ( 1997 ) . Multiple sclerosis: Variants on a theme . Immunology Today vol. 18 , ( 8 ) 368 - 371 .
Bolton C, O¿ Neill JK, Allen SJ, Baker D ( 1997 ) . Regulation of Chronic Relapsing Experimental Allergic Encephalomyelitis by Endogenous and Exogenous Glucocorticoids . International Archives of Allergy and Immunology vol. 114 , ( 1 ) 74 - 80 .
Brennan FR, ONeill JK, Allen SJ, Mikecz K, Glant TT, Nuki G, Baker D ( 1996 ) . Anti-CD44 antibody prevents and ameriolates chronic relapsing experimental allergic encephalomyelitis (CREAE) by inhibition leukocyte migration to the CNS . ARTHRITIS AND RHEUMATISM vol. 39 , ( 9 ) 625 - 625 .
Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, Baker D ( 1996 ) . Encephalitogenic epitopes of myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2A<sup>g7</sup>) mice share an amino acid motif . Journal of Immunology vol. 156 , ( 8 ) 3000 - 3008 .
Baker D, Rosenwasser OA, O'Neill JK, Turk JL ( 1995 ) . Genetic analysis of experimental allergic encephalomyelitis in mice . Journal of Immunology vol. 155 , ( 8 ) 4046 - 4051 .
Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M ( 1994 ) . Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins . European Journal of Immunology vol. 24 , ( 9 ) 2040 - 2048 .
Preece NE, Amor S, Baker D, Gadian DG, O'Neill JK, Urenjak J ( 1994 ) . Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of biozzi mice . Magnetic Resonance in Medicine vol. 32 , ( 6 ) 692 - 697 .
Preece NE, Baker D, Butter C, Gadian DG, Urenjak J ( 1993 ) . Experimental allergic encephalomyelitis raises betaine levels in the spinal cord of strain 13 guinea-pigs . NMR Biomed vol. 6 , ( 3 ) 194 - 200 .
Liu GY, Baker D, Fairchild S, Figueroa F, Quartey-Papafio R, Tone M, Healey D, Cooke A et al. ( 1993 ) . Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules . Immunogenetics vol. 37 , ( 4 ) 296 - 300 .
O'Neill JK, Baker D, Davidson AN, Allen SJ, Butter C, Waldmann H, Turk JL ( 1993 ) . Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies . Journal of Neuroimmunology vol. 45 , ( 1-2 ) 1 - 14 .
Allen SJ, Baker D, O¿Neill JK, Davison AN, Turk JL ( 1993 ) . Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the biozzi ab/h mouse . Cellular Immunology vol. 146 , ( 2 ) 335 - 350 .
O'Neill JK, Baker D, Turk JL ( 1992 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse . Journal of Neuroimmunology vol. 41 , ( 2 ) 177 - 187 .
O'Neill JK, Baker D, Davison AN, Maggon KK, Jaffee BD, Turk JL ( 1992 ) . Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium . Journal of Neuroimmunology vol. 38 , ( 1-2 ) 53 - 62 .
Butter C, O'Neill JK, Baker D, Gschmeissner SE, Turk JL ( 1991 ) . An immunoelectron microscopical study of the expression of class II major histocompatibility complex during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neuroimmunol vol. 33 , ( 1 ) 37 - 42 .
Butter C, Baker D, O'Neill JK, Turk JL ( 1991 ) . Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neurol Sci vol. 104 , ( 1 ) 9 - 12 .
Baker D, O'Neill JK, Amor S, Khamashta MA, Turk JL ( 1991 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH<inf>3</inf> . International Journal of Immunopharmacology vol. 13 , ( 4 ) 385 - 392 .
Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL ( 1991 ) . Suppression of demyelination by mitoxantrone . Int J Immunopharmacol vol. 13 , ( 7 ) 923 - 930 .
Wilcox CE, Ward AM, Evans A, Baker D, Rothlein R, Turk JL ( 1990 ) . Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 30 , ( 1 ) 43 - 51 .
Butter C, Healey DG, Baker D, Turk JL ( 1989 ) . A quantitative immunocytochemical study of the infiltrating lymphocytes in the spinal cord of guinea pigs with chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 25 , ( 2-3 ) 169 - 176 .
Wilcox CE, Healey DG, Baker D, Willoughby DA, Turk JL ( 1989 ) . Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis . Immunology vol. 67 , ( 4 ) 435 - 440 .
Wilcox CE, Baker D, Butter C, Willoughby DA, Turk JL ( 1989 ) . Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis . Cell Immunol vol. 120 , ( 1 ) 82 - 91 .
BAKER D, PARKER DD, TURK JL ( 1985 ) . Effect of depletion of epidermal dendritic cells on the induction of contact sensitivity in the guinea‐pig . British Journal of Dermatology vol. 113 , ( 3 ) 285 - 294 .